About ACADIA Pharmaceuticals (NASDAQ:ACAD)
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$124.90 million
Price / Sales25.71
Price / CashN/A
Book Value$2.70 per share
Price / Book9.54
Return on Equity-73.02%
Return on Assets-65.87%
ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions
What is ACADIA Pharmaceuticals' stock symbol?
ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."
How were ACADIA Pharmaceuticals' earnings last quarter?
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.58) by $0.03. The biopharmaceutical company earned $43.56 million during the quarter, compared to analyst estimates of $45.30 million. ACADIA Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 231.71%. View ACADIA Pharmaceuticals' Earnings History.
When will ACADIA Pharmaceuticals make its next earnings announcement?
Where is ACADIA Pharmaceuticals' stock going? Where will ACADIA Pharmaceuticals' stock price be in 2018?
12 Wall Street analysts have issued 1 year target prices for ACADIA Pharmaceuticals' shares. Their predictions range from $45.00 to $61.00. On average, they expect ACADIA Pharmaceuticals' share price to reach $51.27 in the next year. View Analyst Ratings for ACADIA Pharmaceuticals.
What are Wall Street analysts saying about ACADIA Pharmaceuticals stock?
Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (1/24/2018)
- 2. HC Wainwright analysts commented, "HARMONY Study Initiation: Killing Multiple" Birds With One Stone? Reit Buy and $60 PT Initiation of the Ph3 HARMONY study is one step forward with our bull thesis. With the initiation of HARMONY study in dementia-related psychosis (DRP) and discontinuation of SEREN study in AD agitation, we applaud what we view as a smart move by Acadia of pursuing a broader indication for pimavanserin, and more importantly, doing so with a solid clinical plan moving forward. At first glance, the seemingly bold move into DRP from ADP may appear over-ambitious (killing multiple" birds with one stone). However, we note that a psychosis focus/approach may prove to be a smart play from both the commercial point of view and also from the mechanistic perspective. The blessing from the FDA with a Breakthrough Designation further elevates our sanguine outlook for the program. We highlight the significant upside coming with the DRP expansion as the target market is potentially bigger than ADP alone (if we assume ADP comprises 70% of the DRP)." (10/5/2017)
Are investors shorting ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals saw a decline in short interest during the month of February. As of February 28th, there was short interest totalling 10,355,126 shares, a decline of 10.7% from the February 15th total of 11,594,386 shares. Based on an average trading volume of 2,742,978 shares, the short-interest ratio is presently 3.8 days. Currently, 9.2% of the shares of the stock are short sold.
Who are some of ACADIA Pharmaceuticals' key competitors?
Some companies that are related to ACADIA Pharmaceuticals include EXACT Sciences (EXAS), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), BIO-TECHNE (TECH), Galapagos (GLPG), Sarepta Therapeutics (SRPT), AveXis (AVXS), United Therapeutics (UTHR), Swedish Orphan Bio (SWTUY), Orion (ORINY), Blueprint Medicines (BPMC), Integra Lifesciences (IART), FibroGen (FGEN), Indivior (INVVY), Taro Pharmaceutical Industries (TARO), ABLYNX (ABLYF), Hikma Pharmaceutic (HKMPF) and Ligand Pharmaceuticals (LGND).
Who are ACADIA Pharmaceuticals' key executives?
ACADIA Pharmaceuticals' management team includes the folowing people:
- Stephen R. Biggar M.D. Ph.D., Chairman of the Board (Age 46)
- Stephen R. Davis, President, Chief Executive Officer, Director (Age 56)
- Todd S. Young, Executive Vice President, Chief Financial Officer (Age 45)
- Glenn F. Baity, Executive Vice President, General Counsel, Secretary (Age 47)
- Srdjan Stankovic M.D., Executive Vice President, Head - Research and Development (Age 60)
- Michael J. Yang, Executive Vice President, Chief Commercial Officer (Age 55)
- Edmund P. Harrigan M.D., Director (Age 64)
- Julian C. Baker, Independent Director (Age 50)
- Laura A. Brege, Independent Director (Age 59)
- James M. Daly, Independent Director (Age 55)
Who owns ACADIA Pharmaceuticals stock?
ACADIA Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.40%), OppenheimerFunds Inc. (3.87%), Franklin Resources Inc. (2.61%), Fred Alger Management Inc. (1.74%), First Trust Advisors LP (1.23%) and Goldman Sachs Group Inc. (0.96%). Company insiders that own ACADIA Pharmaceuticals stock include Bros Advisors Lp Baker, Daniel B Soland, Edmund Harrigan, Glenn Baity, Laura Brege, Leslie L Iversen and Terrence O Moore. View Institutional Ownership Trends for ACADIA Pharmaceuticals.
Who sold ACADIA Pharmaceuticals stock? Who is selling ACADIA Pharmaceuticals stock?
ACADIA Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., OppenheimerFunds Inc., Frontier Capital Management Co. LLC, TIAA CREF Investment Management LLC, Deutsche Bank AG, Macquarie Group Ltd., QVT Financial LP and Wells Fargo & Company MN. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Glenn Baity and Laura Brege. View Insider Buying and Selling for ACADIA Pharmaceuticals.
Who bought ACADIA Pharmaceuticals stock? Who is buying ACADIA Pharmaceuticals stock?
ACADIA Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., First Trust Advisors LP, Sectoral Asset Management Inc, Tekla Capital Management LLC, Wealthstreet Investment Advisors LLC, Sphera Funds Management LTD., Franklin Resources Inc. and Fred Alger Management Inc.. Company insiders that have bought ACADIA Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Daniel B Soland and Edmund Harrigan. View Insider Buying and Selling for ACADIA Pharmaceuticals.
How do I buy ACADIA Pharmaceuticals stock?
Shares of ACADIA Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ACADIA Pharmaceuticals' stock price today?
One share of ACADIA Pharmaceuticals stock can currently be purchased for approximately $25.75.
How big of a company is ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals has a market capitalization of $3.21 billion and generates $124.90 million in revenue each year. The biopharmaceutical company earns $-289,400,000.00 in net income (profit) each year or ($2.35) on an earnings per share basis. ACADIA Pharmaceuticals employs 425 workers across the globe.
How can I contact ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]
MarketBeat Community Rating for ACADIA Pharmaceuticals (ACAD)MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
ACADIA Pharmaceuticals (NASDAQ:ACAD) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.83||2.83||2.83||2.75|
|Ratings Breakdown: ||0 Sell Rating(s)|
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
3 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$51.27||$51.27||$49.42||$44.17|
|Price Target Upside: ||99.12% upside||73.04% upside||66.78% upside||19.92% upside|
ACADIA Pharmaceuticals (NASDAQ:ACAD) Consensus Price Target History
ACADIA Pharmaceuticals (NASDAQ:ACAD) Analyst Ratings History
(Data available from 3/18/2016 forward)
ACADIA Pharmaceuticals (NASDAQ:ACAD) Earnings History and Estimates Chart
ACADIA Pharmaceuticals (NASDAQ ACAD) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/27/2018||Q4 2017||($0.58)||($0.55)||$45.30 million||$43.56 million||View||Listen|
|11/7/2017||Q3 2017||($0.63)||($0.53)||$32.03 million||$35.58 million||View||N/A|
|8/8/2017||Q2 2017||($0.72)||($0.55)||$20.02 million||$30.50 million||View||Listen|
|5/9/2017||Q1 2017||($0.73)||($0.72)||$15.17 million||$15.30 million||View||Listen|
|2/28/2017||Q416||($0.65)||($0.65)||$9.05 million||$12.00 million||View||Listen|
|11/7/2016||Q316||($0.56)||($0.61)||$2.90 million||$5.30 million||View||Listen|
|8/4/2016||Q216||($0.49)||($0.63)||$0.71 million||$0.97 million||View||Listen|
|11/5/2015||Q315||($0.40)||($0.39)||$0.05 million||$0.04 million||View||Listen|
|2/26/2015||Q414||($0.26)||($0.28)||$0.08 million||$0.05 million||View||Listen|
|8/5/2014||Q2||($0.17)||($0.22)||$0.10 million||$0.03 million||View||Listen|
|5/6/2014||Q1||($0.13)||($0.19)||$0.50 million||$0.03 million||View||Listen|
|2/27/2014||Q4||($0.14)||($0.13)||$0.30 million||$0.04 million||View||Listen|
|11/6/2013||Q3 2013||($0.12)||($0.12)||$0.25 million||$0.24 million||View||N/A|
|8/6/2013||Q2 2013||($0.09)||($0.11)||$0.45 million||$451.00 million||View||Listen|
|5/7/2013||Q1 2013||($0.08)||($0.08)||$0.45 million||$0.42 million||View||Listen|
|11/5/2012||Q312||($0.09)||($0.04)||$1.90 million||$3.50 million||View||N/A|
ACADIA Pharmaceuticals (NASDAQ:ACAD) Earnings Estimates
2018 EPS Consensus Estimate: ($1.91)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
No dividend announcements for this company have been tracked by MarketBeat.com
ACADIA Pharmaceuticals (NASDAQ ACAD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 22.25%
Institutional Ownership Percentage: 96.25%
ACADIA Pharmaceuticals (NASDAQ ACAD) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/1/2018||Daniel B Soland||Director||Buy||7,000||$23.91||$167,370.00||2,000|| |
|1/29/2018||Glenn Baity||EVP||Sell||36,558||$32.39||$1,184,113.62||83,734|| |
|1/2/2018||Glenn Baity||EVP||Sell||74,321||$30.14||$2,240,034.94|| |
|1/2/2018||Laura Brege||Director||Sell||25,000||$30.06||$751,500.00||15,000|| |
|10/5/2017||Glenn Baity||EVP||Sell||37,500||$40.91||$1,534,125.00|| |
|8/30/2017||Glenn Baity||EVP||Sell||26,507||$34.87||$924,299.09||94,163|| |
|8/9/2017||Glenn Baity||EVP||Sell||14,322||$34.88||$499,551.36||78,578|| |
|7/20/2017||Glenn Baity||EVP||Sell||38,097||$30.00||$1,142,910.00||109,253|| |
|6/22/2017||Glenn Baity||EVP||Sell||1,903||$30.00||$57,090.00||83,059|| |
|2/16/2017||Terrence O. Moore||EVP||Sell||157,540||$39.77||$6,265,365.80|| |
|12/27/2016||Glenn Baity||EVP||Sell||9,800||$30.46||$298,508.00||81,363|| |
|12/20/2016||Glenn Baity||EVP||Sell||10,000||$30.00||$300,000.00|| |
|8/16/2016||Edmund Harrigan||Director||Buy||1,000||$32.97||$32,970.00||1,000|| |
|8/10/2016||Bros. Advisors Lp Baker||Director||Buy||1,303,030||$33.00||$42,999,990.00|| |
|7/12/2016||Glenn Baity||EVP||Sell||16,000||$35.00||$560,000.00||66,978|| |
|7/11/2016||Glenn Baity||EVP||Sell||4,057||$35.00||$141,995.00||66,978|| |
|4/18/2016||Leslie L Iversen||Director||Sell||33,697||$33.53||$1,129,860.41||69,824|| |
|4/1/2016||Bros. Advisors Lp Baker||Director||Buy||1,449,090||$27.08||$39,241,357.20|| |
|1/7/2016||L.P. 14159||Director||Buy||2,586,206||$29.00||$74,999,974.00|| |
|11/11/2015||Leslie L. Iversen||Director||Sell||30,000||$36.01||$1,080,300.00||36,127|| |
|1/15/2015||Michael T Borer||Director||Sell||27,973||$33.02||$923,668.46|| |
|1/14/2015||Uli Hacksell||CEO||Sell||30,000||$33.98||$1,019,400.00|| |
|12/15/2014||Mary Ann Gray||Director||Sell||12,250||$31.74||$388,815.00|| |
|12/15/2014||Uli Hacksell||CEO||Sell||30,000||$31.00||$930,000.00|| |
|11/26/2014||Michael T Borer||Director||Sell||15,000||$30.05||$450,750.00|| |
|11/26/2014||Roger Mills||CMO||Sell||25,000||$30.09||$752,250.00|| |
|11/24/2014||Uli Hacksell||CEO||Sell||30,000||$29.28||$878,400.00|| |
|11/21/2014||William Mcdowall Wells||Director||Sell||5,810||$29.00||$168,490.00|| |
|10/8/2014||Uli Hacksell||CEO||Sell||30,000||$24.15||$724,500.00|| |
|9/15/2014||Laura Brege||Director||Sell||10,000||$28.07||$280,700.00|| |
|9/12/2014||William Mcdowall Wells||Director||Sell||9,190||$29.15||$267,888.50|| |
|9/10/2014||Uli Hacksell||CEO||Sell||30,000||$27.36||$820,800.00|| |
|8/15/2014||Uli Hacksell||CEO||Sell||15,000||$22.89||$343,350.00|| |
|7/14/2014||Uli Hacksell||CEO||Sell||20,000||$22.22||$444,400.00|| |
|6/16/2014||Uli Hacksell||CEO||Sell||20,000||$23.10||$462,000.00|| |
|6/9/2014||William Mcdowall Wells||Director||Sell||15,000||$23.03||$345,450.00|| |
|5/1/2014||Torsten Rasmussen||Director||Sell||32,857||$20.03||$658,125.71|| |
|4/15/2014||Uli Hacksell||CEO||Sell||25,000||$17.75||$443,750.00|| |
|4/4/2014||Thomas Aasen||CFO||Sell||15,000||$22.48||$337,200.00||23,848|| |
|4/4/2014||Torsten Rasmussen||Director||Sell||30,000||$21.98||$659,400.00|| |
|3/5/2014||Bros. Advisors Lp Baker||Director||Buy||526,316||$28.50||$15,000,006.00|| |
|2/26/2014||Glenn Baity||VP||Sell||42,000||$30.28||$1,271,760.00||47,788|| |
|11/1/2013||Torsten Rasmussen||Director||Sell||37,692||$23.00||$866,916.00|| |
|11/1/2013||Uli Hacksell||CEO||Sell||15,000||$23.24||$348,600.00|| |
|10/10/2013||Laura Brege||Director||Sell||10,000||$21.63||$216,300.00|| |
|10/1/2013||Thomas H Aasen||CFO||Sell||30,000||$27.87||$836,100.00|| |
|9/20/2013||Roger Mills||CMO||Sell||35,965||$25.01||$899,484.65||15,775|| |
|9/12/2013||Lester Ph Kaplan||Director||Sell||66,356||$22.90||$1,519,552.40||8,500|| |
|9/10/2013||Laura Brege||Director||Sell||46,153||$22.80||$1,052,288.40|| |
|9/3/2013||Torsten Rasmussen||Director||Sell||40,000||$20.28||$811,200.00|| |
|8/26/2013||Mary Ann Gray||Director||Sell||15,000||$20.68||$310,200.00|| |
|8/13/2013||Thomas Aasen||CFO||Sell||60,000||$20.15||$1,209,000.00||31,585|| |
|8/13/2013||Uli Hacksell||CEO||Sell||52,771||$20.14||$1,062,807.94|| |
|6/5/2013||Felix Baker||Director||Buy||2,340,314||$14.34||$33,560,102.76|| |
|5/15/2013||Felix Baker||Director||Buy||1,993,000||$12.50||$24,912,500.00|| |
|4/12/2013||Glenn Baity||VP||Sell||60,000||$12.42||$745,200.00|| |
|4/11/2013||Thomas H Aasen||CFO||Sell||40,000||$11.06||$442,400.00|| |
ACADIA Pharmaceuticals (NASDAQ ACAD) News Headlines
ACADIA Pharmaceuticals (NASDAQ:ACAD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
ACADIA Pharmaceuticals (NASDAQ:ACAD) Income Statement, Balance Sheet and Cash Flow Statement
ACADIA Pharmaceuticals (NASDAQ ACAD) Stock Chart for Sunday, March, 18, 2018